Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)
16.89
-0.01 (-0.06%)
Apr 30, 2026, 2:35 PM CST
SHE:002932 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | - | 493.91 | 1,016 | 2,556 | 1,190 |
Short-Term Investments | - | 738.79 | - | 70 | - |
Trading Asset Securities | - | 64.12 | 122.59 | 1,953 | 700 |
Cash & Short-Term Investments | 3,750 | 1,297 | 1,138 | 4,578 | 1,890 |
Cash Growth | 189.20% | 13.93% | -75.14% | 142.22% | 117.48% |
Accounts Receivable | - | 766.95 | 1,254 | 2,736 | 740.42 |
Other Receivables | - | 80.52 | 70.28 | 17.52 | 11.97 |
Receivables | - | 847.47 | 1,324 | 2,754 | 752.39 |
Inventory | - | 82.3 | 128.77 | 258.44 | 284.59 |
Other Current Assets | - | 171.08 | 158.83 | 91.09 | 72.98 |
Total Current Assets | - | 2,398 | 2,750 | 7,682 | 3,000 |
Property, Plant & Equipment | - | 721.68 | 543.6 | 521.59 | 243.47 |
Long-Term Investments | - | 257.61 | 156.36 | 83.49 | 60.62 |
Other Intangible Assets | - | 17.3 | 17.7 | 21.24 | 16.59 |
Long-Term Deferred Tax Assets | - | 216.9 | 210.18 | 173.95 | 16.63 |
Long-Term Deferred Charges | - | 3.11 | 14.87 | 17.21 | 1.45 |
Other Long-Term Assets | - | 2,979 | 3,694 | 695.33 | 78.24 |
Total Assets | - | 6,593 | 7,387 | 9,195 | 3,417 |
Accounts Payable | - | 278.11 | 681.58 | 1,294 | 174.31 |
Accrued Expenses | - | 87.97 | 154.94 | 364.68 | 83.18 |
Short-Term Debt | - | 3 | 23.61 | 164.67 | 30 |
Current Portion of Leases | - | 4.3 | 7.29 | 18.17 | 3.62 |
Current Income Taxes Payable | - | 6.44 | 6.27 | 144.02 | 131.8 |
Current Unearned Revenue | - | 37.96 | 53.17 | 309.58 | 71.18 |
Other Current Liabilities | - | 78.07 | 92.5 | 69.96 | 51.9 |
Total Current Liabilities | - | 495.86 | 1,019 | 2,365 | 545.98 |
Long-Term Leases | - | 5.82 | 18.25 | 20.75 | 10.74 |
Long-Term Unearned Revenue | - | 20.87 | 14.26 | 5.96 | 5.96 |
Long-Term Deferred Tax Liabilities | - | 50.42 | 39.59 | 31.07 | 4.33 |
Other Long-Term Liabilities | - | 1.44 | 3.03 | - | - |
Total Liabilities | - | 574.4 | 1,094 | 2,423 | 567.02 |
Common Stock | - | 232.52 | 232.52 | 156.19 | 104.88 |
Additional Paid-In Capital | - | 818.1 | 820.18 | 887.89 | 904.5 |
Retained Earnings | - | 5,014 | 4,973 | 5,472 | 1,812 |
Treasury Stock | - | -237.95 | - | -16.02 | -32.77 |
Total Common Equity | 5,561 | 5,826 | 6,026 | 6,500 | 2,789 |
Minority Interest | - | 192.29 | 266.21 | 271.92 | 61.25 |
Shareholders' Equity | 5,727 | 6,019 | 6,292 | 6,772 | 2,850 |
Total Liabilities & Equity | - | 6,593 | 7,387 | 9,195 | 3,417 |
Total Debt | 10.75 | 13.11 | 49.16 | 203.59 | 44.36 |
Net Cash (Debt) | 3,740 | 1,284 | 1,089 | 4,375 | 1,846 |
Net Cash Growth | 191.32% | 17.87% | -75.10% | 137.02% | 153.67% |
Net Cash Per Share | 15.90 | 5.68 | 4.80 | 19.03 | 8.72 |
Filing Date Shares Outstanding | 282.39 | 220.05 | 232.52 | 232.73 | 232.84 |
Total Common Shares Outstanding | 282.39 | 220.05 | 232.52 | 232.73 | 232.84 |
Working Capital | - | 1,902 | 1,731 | 5,317 | 2,454 |
Book Value Per Share | 25.34 | 26.48 | 25.92 | 27.93 | 11.98 |
Tangible Book Value | 5,545 | 5,809 | 6,008 | 6,479 | 2,772 |
Tangible Book Value Per Share | 25.26 | 26.40 | 25.84 | 27.84 | 11.91 |
Buildings | - | 440.3 | 116.98 | 116.66 | 78 |
Machinery | - | 380.8 | 402.91 | 374.05 | 158.18 |
Construction In Progress | - | 120.79 | 185.19 | 121.52 | 73.58 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.